Home/Ona Therapeutics/Haijun Sun, PhD, MBA

HS

Haijun Sun, PhD, MBA

Chief Scientific Officer

Ona Therapeutics

Therapeutic Areas

Ona Therapeutics Pipeline

Drug	Indication	Phase
ONA-255	Refractory Breast Cancer and Solid Tumors	Pre-clinical
ONA-389	Prevalent Solid Tumors	Pre-clinical

Leadership Team at Ona Therapeutics

Valerie Vanhooren, PhD

Co-founder and Chief Executive Officer

Mercè de Frias, PhD, MBA

Chief Operating Officer

Jutta Amersdorffer, Dr med, MBA

Chief Medical Officer

Beatriz Morancho, PhD

Research Director

Antoine J. Yver

Independent Chair of the Board

View full Ona Therapeutics profile